CareDx, which sells molecular diagnostic tests to monitor heart transplants, raised $40 million in a downsized IPO by offering 4.0 million shares at $10, well below the range of $15 to $17. The company originally planned to raise $50 million by offering 3.1...read more
CareDx, which sells molecular diagnostic tests to monitor heart transplants, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $50 million by offering 3.1 million shares at a price range of $15 to $17. At the midpoint of the...read more
CareDx, which sells molecular diagnostic tests to monitor heart transplants, refiled on Tuesday with the SEC to raise up to $50 million in an initial public offering. It originally filed for an $86 million IPO in 2007 under the name XDx but withdrew in 2008.
...read more
CareDx prices downsized IPO at $10, well below the range
CareDx, which sells molecular diagnostic tests to monitor heart transplants, raised $40 million in a downsized IPO by offering 4.0 million shares at $10, well below the range of $15 to $17. The company originally planned to raise $50 million by offering 3.1...read more
11 US IPOs planned for the week of Jul 14
The following IPOs are expected to price this week: CareDx (CDNA), which sells molecular diagnostic tests to monitor heart transplants, plans to raise $50 million by...read more
Heart transplant monitor company CareDx sets terms for $50 million IPO
CareDx, which sells molecular diagnostic tests to monitor heart transplants, announced terms for its IPO on Monday. The Brisbane, CA-based company plans to raise $50 million by offering 3.1 million shares at a price range of $15 to $17. At the midpoint of the...read more
Heart transplant monitor company CareDx refiles for a $50 million IPO
CareDx, which sells molecular diagnostic tests to monitor heart transplants, refiled on Tuesday with the SEC to raise up to $50 million in an initial public offering. It originally filed for an $86 million IPO in 2007 under the name XDx but withdrew in 2008. ...read more